Back to search results
NCT06664866

AI Echocardiographic Screening of Cardiac Amyloidosis

Enrolling by Invitation
NAAges 22+InterventionalDiagnostic
Cedars-Sinai Medical Center
~500 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:EchoNet-LVH Assessment

At a glance

Recruiting sites
0 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Positive Predictive Value
Measured over 1 year

Conditions

Cardiac Amyloidosis

Explore related trials

Cardiac Amyloidosis

NCT06664866

Where you'd take part

This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Cedars Sinai Medical Center

    Los Angeles, Californiano site contact published

  • Northwestern Medicine

    Chicago, Illinoisno site contact published

  • Palo Alto Veteran Affairs Hospital

    Palo Alto, Californiano site contact published

  • Providence Heart and Vascular Institute

    Portland, Oregonno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Lily Stern, MD · PRINCIPAL_INVESTIGATOR · Cedars-Sinai Medical Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients receiving an echocardiogram that is determined to be suspicious by EchoNet-LVH

Exclusion

Patients that decline consent
Patients receiving an echocardiogram that is determined to be not suspicious by EchoNet-LVH

What this trial measures

  • Positive Predictive Value1 year

    1. Among patients that screening positive and consented to the trial, the proportion of patients that subsequently are confirmed to have CA upon clinical follow-up. 2. Statistical Analysis: Fisher's exact (two-sided) for superiority Comparison with PPV of standard clinical suspicion (PPV of all comers that receive Tc-99m PYP/HDP imaging scan or other clinical diagnosis).